UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
UBS analyst Dan Brennan maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target from $2.5 to $8.
UBS analyst Dan Brennan maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target from $2.5 to $8.